2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Chemical Properties

Boiling point:

630.2±55.0 °C(Predicted)

Density 

1.182±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml)

form 

solid

pka

2.34±0.20(Predicted)

color 

White

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)- Usage And Synthesis

Description

PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1

Uses

BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers.

in vitro

pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1].

IC 50

0.006-0.10 μm

References

1) Chupak?et al. (2015), Compounds Useful as Immunomodulators; WO2015/034820

2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-(1675201-83-8)Related Product Information

• ZM 447439
• AAL-993
• Brefeldin A
• SU 4312
• BMS-986020
• BMS-852927
• XL-652
• BMS-986142
• BMS 303141
• BMS813160
• Insulin-like Growth Factor-1 Receptor Inhibitor
• PD-L1 inhibitor 1
• AC480 (BMS-599626)
• BMS-986205
• 3-chloro-2-(1,1-difluorobut-3-enyl)-6-methoxyquinoxaline
• GSK591